• Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
Wednesday, November 18, 2026
No Result
View All Result
Subscribe Now
  • Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Trump Administration Revokes Pay Increase for Head Start Educators

    Trump Administration Revokes Pay Increase for Head Start Educators

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
The Insight Post
  • Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Trump Administration Revokes Pay Increase for Head Start Educators

    Trump Administration Revokes Pay Increase for Head Start Educators

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
No Result
View All Result
No Result
View All Result
Home Science

What Have We Learned From Intentionally Infecting People With Covid-19?

by Theinsightpost
January 12, 2025
in Science
0 0
0
What Have We Learned From Intentionally Infecting People With Covid-19?

The world’s first Covid-19 human challenge study was born in early 2021.
Sorbetto via Getty Images

When the Covid-19 pandemic first struck, Christopher Chiu and other researchers wondered: Should they inject healthy people with the virus that caused the pandemic?

The idea sounded counterintuitive, but by carefully dosing individuals with SARS-CoV-2 in a controlled setting—as Chiu had been doing for more than a decade with seasonal flu and RSV—scientists could study how the virus affects the body and learn what factors may offer protective benefits.

These types of studies, called human challenge trials, could help fast-track understanding of the deadly virus devastating the world, experts claimed. Others, though, questioned whether the potential benefits were worth the risk, particularly given the host of unknowns surrounding Covid-19, and the lack of available treatments at the time.

After months of deliberation among doctors, scientists, ethicists and regulators, the world’s first Covid-19 human challenge study was ultimately born in early 2021. And Chiu, an infectious disease physician and immunologist at Imperial College London, was its chief investigator: “We sort of recognized that there were still lots of things we didn’t know about how the disease happens.”

Early insights helped guide U.K. public policy on isolation times. Nearly four years later, more results are starting to emerge: One recent study published in eClinicalMedicine, one of the Lancet’s open-access journals, suggests individuals who got infected performed worse on cognitive tests than those who didn’t—a finding that may speak to long Covid and the cognitive effects of infection but that has received pushback from other experts. Another 2024 study points to a protein that might help protect against Covid-19. And the most recent study found that certain blood biomarkers may help researchers stratify patients for different treatments.

For Chiu, these studies were a success. And researchers continue to conduct challenge trials with the goal of developing better vaccines than the ones on the market and now want to expand trials to other countries.

Yet some skeptics argue none of these challenge trials were necessary, and that many of the findings could have been gleaned through other types of studies. The challenge trials, for instance, didn’t directly inform vaccine or treatment development, raising questions about whether these risks were justified.

“Did we really learn?” said Marc Veldhoen, an immunologist at the University of Lisbon and Gulbenkian Institute for Molecular Medicine. “Not so much.”


Human challenge trials have been going on in some form since the 1700s—and they’ve long been controversial. In recent decades, the trials have become more scientifically rigorous but have continued to spark ethical concerns surrounding potential risk and subject exploitation.

Still, they have persisted due to several key advantages.

For one, because researchers control the type of virus and dose, they’re able to better attribute cause to effects. “If a patient does something weird or has a unique response, you never know why that exactly is. Is it because of comorbidities? Is it because this person happened to have been exposed to a massive dose?” said Rik Lindeboom, an immunologist at the Netherlands Cancer Institute in Amsterdam. “With these challenge studies, you can really control for all of this, and that makes them very, very unique.”

Scientists can also control the time of exposure, allowing them to pinpoint how long it takes for someone to become infectious and develop symptoms. Indeed, one of the first Covid-19 challenge trial papers, published in 2022, found that individuals started to shed SARS-CoV-2 after just two days of infection and that they could remain contagious for another ten. Participants with a negative Covid-19 test were not shedding virus, they also found.

At the time, this information had a direct impact on public health decision-making in the United Kingdom, said Chiu, and led to the recommended isolation period of ten days: “With this research, we were able to really clearly define when you could come out of self-isolation.” Other studies revealed that some people naturally shed large amounts of virus and that people’s bodies fight off infection by increasing an immune pathway called the interferon response, providing a potential target mechanism to help reduce transmission and disease.

More recently, challenge trials have given insight into a unique population that might otherwise not be studied: those who don’t get infected after exposure. In a Nature study published in June 2024, Chiu and colleagues exposed 16 participants to SARS-CoV-2, yet only six developed a sustained infection. Then, Lindeboom studied the immune cells from these participants and found that the people who avoided infection all shared a high expression of a gene the researchers think could potentially protect against infection, said Lindeboom.

Meanwhile, the recent eClinicalMedicine study compared infected and uninfected participants on a set of cognitive tests. The 18 infected participants performed worse than the 16 who did not become infected, particularly in tests that measured memory and executive function. These changes persisted for at least a year, suggesting that the virus could have lasting effects on cognitive function.

That study, though, has received some criticism. Veldhoen, the immunologist in Lisbon, pointed out that the differences between the groups were variable and modest. “If you look at all the tests individually, I think there’s only one or two where there is indeed a difference—the difference is quite small,” said Veldhoen, noting that when it comes down to whether the work was necessary, he is “still not completely convinced.”


Indeed, not everyone agreed that the challenge trials were worth the risk. For example, U.S. institutions decided not to approve such trials, in part because, at the time, clinicians lacked an effective treatment for severe cases—typically a key consideration in conducting challenge trials. And while none of the studies conducted t -date have reported serious adverse events such as hospitalizations, some experts question whether more challenge trials are worth the gamble, particularly given the question marks surrounding long Covid.

The decision to infect someone with a pathogen needs to be outweighed by clear and obvious benefits, said Angela Huttner, an infectious disease physician at Geneva University Hospital in Switzerland. “If you’re going to sacrifice one person, it better be for the good of more than one person,” she said. Before the studies were conducted, she and others thought that Covid-19 failed to meet those criteria. Now the lack of what they consider meaningful results confirms their worries.

Meanwhile, some experts say that challenge trials may not be necessary given the prevalence of Covid-19. In the United States, “we were able to conduct the huge Phase 3 trials with 30-40,000 participants per vaccine,” wrote Kirsten Lyke, an infectious disease specialist at the University of Maryland, in an email to Undark.

By comparison, challenge trial studies typically attract fewer than 100 subjects. The 2022 Nature study, for example, included just 36 young and healthy volunteers. Veldhoen noted that the small sample size limits the research’s statistical power and generalizability: “It’s super difficult to get the bigger picture from those studies,” he said. Huttner agrees: “You can glean some information, but it may be clinically very limited.”

The findings also did not result in a new vaccine or treatment, as some experts have pointed out. “I’m not convinced that Covid-19 human challenge models turned out to be critical to the effort to develop biologics, vaccines and therapeutics,” Lyke wrote in her email.

Chiu, meanwhile, argues that although current vaccines effectively prevent serious disease and death, they are subpar in stopping the spread. Challenge trials, he said, can help develop better vaccines.

In fact, Chiu leads a new initiative that intends to do just that: The Mucosal Immunity in Human Coronavirus Challenge, or MusiCC, project has received $57 million to develop experimental vaccines to block transmission. The global consortium also aims to increase the capacity to conduct challenge trials worldwide, Chiu said.

Chiu and a group of collaborators at the University of Oxford led by Helen McShane, an infectious disease physician, are also now recruiting for their next challenge trial in which they will infect participants with the Omicron strain. Meanwhile, another research group in Singapore is currently recruiting for a study on the Delta variant.

While some experts have dismissed insights gleaned from the last few years of challenge trials—“We haven’t learned something that we wouldn’t have gotten in another way,” said Veldhoen—justification for the trials looks different for Chiu.

“It is subjective how much you think scientific findings are worth and their value and their potential impact for the future. So, again, it’s always a conversation to be had, and I would never sort of stop people from criticizing,” he said. “Each new study is a new discussion, and you have to weigh things up again.”

Claudia López Lloreda is a senior contributor at Undark and a freelance science journalist covering life sciences, health care and medicine.

This article was originally published on Undark. Read the original article.

Get the latest Science stories in your inbox.

Filed Under:

COVID-19,

COVID-19 Culture,

Disease,

Disease and Illnesses,

Health,

Medicine,

Microbes, Bacteria, Viruses,

Pandemic,

Viruses

ShareTweetSend
Previous Post

After an ‘unexpectedly difficult’ year, what’s ahead for the Royal Family in 2025?

Next Post

Take a hike – Ten of Aotearoa’s best walks

Related News

Groundbreaking Electric Comb Promises Hair Regrowth in Mice Within Four Weeks, Paving the Way for Future Hair-Loss Solutions
Science

Groundbreaking Electric Comb Promises Hair Regrowth in Mice Within Four Weeks, Paving the Way for Future Hair-Loss Solutions

November 18, 2026
Miniature LSD Doses Administered in Rapid Succession Show Antidepressant Potential in Mice: Exploring the Impact of Timing vs. Tolerance
Science

Miniature LSD Doses Administered in Rapid Succession Show Antidepressant Potential in Mice: Exploring the Impact of Timing vs. Tolerance

November 14, 2026
Investigation Underway: Experts Seek Answers Behind Sudden Brooklyn Building Collapse
Science

Investigation Underway: Experts Seek Answers Behind Sudden Brooklyn Building Collapse

November 12, 2026
Preserve the Unseen: The Essential Role of Parasites in Ecosystems
Science

Preserve the Unseen: The Essential Role of Parasites in Ecosystems

November 11, 2026
Next Post
Take a hike – Ten of Aotearoa’s best walks

Take a hike - Ten of Aotearoa's best walks

Discussion about this post

Subscribe To Our Newsletters

    Customer Support


    1251 Wilcrest Drive
    Houston, Texas
    77042 USA
    Call-832.795.1420
    e-mail – news@theinsightpost.com

    Subscribe To Our Newsletters

      Categories

      • Africa
      • Africa-East
      • African Sports
      • American Sports
      • Arts
      • Asia
      • Australia
      • Business
      • Business Asia
      • Business- Africa
      • Canada
      • Defense
      • Education
      • Egypt
      • Energy
      • Entertainment
      • Europe
      • European Soccer
      • Finance
      • Germany
      • Ghana
      • Health
      • Insight
      • International
      • Investing
      • Japan
      • Latest Headlines
      • Life & Living
      • Markets
      • Mobile
      • Movies
      • New Zealand
      • Nigeria
      • Politics
      • Scholarships
      • Science
      • South Africa
      • South America
      • Sports
      • Tech
      • Travel
      • Travel-Africa
      • UK
      • USA
      • Weather
      • World
      No Result
      View All Result

      Recent News

      The Critical Role of ADCCE in Shaping Today’s Global Landscape

      The Critical Role of ADCCE in Shaping Today’s Global Landscape

      November 18, 2026
      La La Anthony and Ciara Show Their Support for Kiyan Anthony at Madison Square Garden

      La La Anthony and Ciara Show Their Support for Kiyan Anthony at Madison Square Garden

      November 18, 2026
      Transforming American Global Health Aid: A New Era Begins

      Transforming American Global Health Aid: A New Era Begins

      November 18, 2026
      Elon Musk Scores Big with Witty Retort to Democratic Allegations of Wrongdoing

      Elon Musk Scores Big with Witty Retort to Democratic Allegations of Wrongdoing

      November 18, 2026
      • Home
      • Advertise With Us
      • About Us
      • Corporate
      • Consumer Rewards
      • Forum
      • Privacy Policy
      • Social Trends

      Theinsightpost ©2026 | All Rights Reserved. Theinsightpost is an Elnegy LLC company, registered in Texas, USA

      Welcome Back!

      Login to your account below

      Forgotten Password?

      Retrieve your password

      Please enter your username or email address to reset your password.

      Log In

      Add New Playlist

      We are using cookies to give you the best experience on our website.

      You can find out more about which cookies we are using or switch them off in .

      No Result
      View All Result
      • Home
      • Insight
      • Blog
      • Business
      • Entertainment
      • Health
      • Politics
      • Shop
        • Gift Shop
        • Value Shop
        • Store
        • Bargain Shop
        • Discount
      • Sports
      • Tech
      • Travel
      • USA
      • Video
      • World
        • Asia
        • Africa
        • South America
        • North America
        • Europe
        • Oceania

      Theinsightpost ©2026 | All Rights Reserved. Theinsightpost is an Elnegy LLC company, registered in Texas, USA

      The Insight Post
      Powered by  GDPR Cookie Compliance
      Privacy Overview

      This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

      Strictly Necessary Cookies

      Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

      Cookie Policy

      More information about our Cookie Policy